Skip to main content

Advertisement

SpringerLink
Log in

Contemporary treatment of metastatic renal cell carcinoma

  • Review Article
  • Published:
Medical Oncology Aims and scope Submit manuscript

Abstract

Renal cell carcinoma is the 14th most common cancer worldwide. It is a heterogeneous group of histopathological entities, of which the most common is clear cell renal cell carcinoma. Approximately 20–30% of patients present initially with metastatic disease and an additional 20% will progress after radical surgical treatment. Metastatic disease that is non-feasible for surgical treatment remains incurable. Numerous studies have demonstrated that—with the introduction of new drugs—the treatment outcomes of metastatic disease have improved. The development of new therapies as well as the optimization and individualization of procedures allow us to hope for further progress in this area.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Muglia VF, Prando A. Renal cell carcinoma: histological classification and correlation with imaging findings. Radiol Bras. 2015 48(3):166–74. https://doi.org/10.1590/01003984.2013.1927.

    Article  PubMed  PubMed Central  Google Scholar 

  2. Ferlay J, Parkin DM, Steliarova-Foucher E. Estimates of cancer incidence and mortality in Europe in 2008. Eur J Cancer. 2010 46(4):765–81. https://doi.org/10.1016/j.ejca.2009.12.014.

    Article  CAS  PubMed  Google Scholar 

  3. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer. 2010 127(12):2893–917. https://doi.org/10.1002/ijc.25516.

    Article  CAS  PubMed  Google Scholar 

  4. Ljungberg B, Campbell SC, Choi HY, Jacqmin D, Lee JE, Weikert S, Kiemeney LA. The epidemiology of renal cell carcinoma. Eur Urol. 2011 60(4):615–21. https://doi.org/10.1016/j.eururo.2011.06.049.

    Article  PubMed  Google Scholar 

  5. Escudier B, Porta C, Schmidinger M, Rioux-Leclercq N, Bex A, Khoo V, Gruenvald V, Horwich A, ESMO Guidelines Committee. Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2016 27(suppl 5):v58–68.

    Article  CAS  PubMed  Google Scholar 

  6. Mittal K, Koon H, Elson P, Triozzi P, Dowlati A, Chen H, Borden EC, Rini BI. Dual VEGF/VEGFR inhibition in advanced solid malignancies: clinical effects and pharmacodynamic biomarkers. Cancer Biol Ther. 2014 15(8):975–81. https://doi.org/10.4161/cbt.29187.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  7. Pfaffenroth EC, Linehan WM. Genetic basis for kidney cancer: opportunity for disease-specific approaches to therapy. Expert Opin Biol Ther. 2008 8(6):779–90. https://doi.org/10.1517/14712598.8.6.779.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  8. Shuin T, Kondo K, Torigoe S, Kishida T, Kubota Y, Hosaka M, Nagashima Y, Kitamura H, Latif F, Zbar B, et al. Frequent somatic mutations and loss of heterozygosity of the von Hippel-Lindau tumor suppressor gene in primary human renal cell carcinomas. Cancer Res. 1994 54(11):2852–5.

    CAS  PubMed  Google Scholar 

  9. Coleman JA. Familial and hereditary renal cancer syndromes. Urol Clin N Am. 2008 35(4):563–72. https://doi.org/10.1016/j.ucl.2008.07.014.

    Article  Google Scholar 

  10. Athar U, Gentile TC. Treatment options for metastatic renal cell carcinoma: a review. Can J Urol. 2008 15(2):3954–66.

    PubMed  Google Scholar 

  11. Gupta K, Miller JD, Li JZ, Russell MW, Charbonneau C. Epidemiologic and socioeconomic burden of metastatic renal cell carcinoma (mRCC): a literature review. Cancer Treat Rev. 2008 34(3):193–205. https://doi.org/10.1016/j.ctrv.2007.12.001.

    Article  PubMed  Google Scholar 

  12. Leibovich BC, Blute ML, Cheville JC, Lohse CM, Frank I, Kwon ED, Weaver AL, Parker AS, Zincke H. Prediction of progression after radical nephrectomy for patients with clear cell renal cell carcinoma: a stratification tool for prospective clinical trials. Cancer. 2003 97(7):1663–71.

    Article  PubMed  Google Scholar 

  13. Bianchi M, Sun M, Jeldres C, Shariat SF, Trinh QD, Briganti A, Tian Z, Schmitges J, Graefen M, Perrotte P, Menon M, Montorsi F, Karakiewicz PI. Distribution ofmetastatic sites in renal cell carcinoma: a population-based analysis. Ann Oncol. 2012 23(4):973–80. https://doi.org/10.1093/annonc/mdr362.

    Article  CAS  PubMed  Google Scholar 

  14. Motzer RJ, Mazumdar M, Bacik J, Berg W, Amsterdam A, Ferrara J. Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma. J Clin Oncol. 1999 17(8):2530–40.

    Article  CAS  PubMed  Google Scholar 

  15. Motzer RJ, Escudier B, Bukowski R, Rini BI, Hutson TE, Barrios CH, Lin X, Fly K, Matczak E, Gore ME. Prognostic factors for survival in 1059 patients treated with sunitinib for metastatic renal cell carcinoma. Br J Cancer. 2013 108(12):2470–7. https://doi.org/10.1038/bjc.2013.236.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  16. Heng DY, Xie W, Regan MM, Warren MA, Golshayan AR, Sahi C, Eigl BJ, Ruether JD, Cheng T, North S, Venner P, Knox JJ, Chi KN, Kollmannsberger C, McDermott DF, Oh WK, Atkins MB, Bukowski RM, Rini BI, Choueiri TK. Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study. J Clin Oncol. 2009 27(34):5794–9. https://doi.org/10.1200/JCO.2008.21.4809.

    Article  CAS  PubMed  Google Scholar 

  17. Heng DY, Xie W, Regan MM, Harshman LC, Bjarnason GA, Vaishampayan UN, Mackenzie M, Wood L, Donskov F, Tan MH, Rha SY, Agarwal N, Kollmannsberger C, Rini BI, Choueiri TK. External validation and comparison with other models of the International Metastatic Renal-Cell Carcinoma Database Consortium prognostic model: a population-based study. Lancet Oncol. 2013 14(2):141–8. https://doi.org/10.1016/S1470-2045(12)70559-4.

    Article  PubMed  PubMed Central  Google Scholar 

  18. Kubackova K, Melichar B, Bortlicek Z, Pavlik T, Poprach A, Svoboda M, Lakomy R, Vyzula R, Kiss I, Dusek L, Prausova J, Buchler T, Czech Renal Cancer Cooperative Group. Comparison of two prognostic models in patients with metastatic renal cancer treated with Sunitinib: a retrospective, registry-based study. Target Oncol. 2015 10(4):557–63. https://doi.org/10.1007/s11523-015-0366-9.

    Article  PubMed  Google Scholar 

  19. Flanigan RC, Salmon SE, Blumenstein BA, Bearman SI, Roy V, McGrath PC, Caton JR Jr, Munshi N, Crawford ED. Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer. N Engl J Med. 2001 345(23):1655–9.

    Article  CAS  PubMed  Google Scholar 

  20. Conti SL, Thomas IC, Hagedorn JC, Chung BI, Chertow GM, Wagner TH, Brooks JD, Srinivas S, Leppert JT. Utilization of cytoreductive nephrectomy and patient survival in the targeted therapy era. Int J Cancer. 2014 134(9):2245–52.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  21. Mejean A, Escudier B, Thezenas S, Beauval JB, Geoffroy L, Bensalah K, Thiery-Vuillemin A, Cormier L, Lang H, Guy L, Gravis G, Rolland F, Linassier C, Timsit MO, Albiges L, Beisland C, Aitchison M, Colas S, Lebret T, Ravaud A. CARMENA: Cytoreductive nephrectomy followed by sunitinib versus sunitinib alone in metastatic renal cell carcinoma—results of a phase III noninferiority trial. J Clin Oncol. 2018 36(18_suppl): LBA3–LBA3.

    Article  Google Scholar 

  22. Dabestani S, Marconi L, Hofmann F, Stewart F, Lam TB, Canfield SE, Staehler M, Powles T, Ljungberg B, Bex A. Local treatments for metastases of renal cell carcinoma: a systematic review. Lancet Oncol. 2014 15(12):e549-61. https://doi.org/10.1016/S1470-2045(14)70235-9.

    Article  PubMed  Google Scholar 

  23. Dabestani S, Marconi L, Bex A. Metastasis therapies for renal cancer. Curr Opin Urol. 2016 26(6):566–72.

    Article  PubMed  Google Scholar 

  24. Marulli G, Sartori F, Bassi PF, dal Moro F, Gino Favaretto A, Rea F. Long-term results of surgical management of pulmonary metastases from renal cell carcinoma. Thorac Cardiovasc Surg. 2006 54(8):544–7.

    Article  CAS  PubMed  Google Scholar 

  25. Meimarakis G, Angele M, Staehler M, Clevert DA, Crispin A, Rüttinger D, Löhe F, Preissler G, Hatz RA, Winter H. Evaluation of a new prognostic score (Munich score) to predict long term survival after resection of pulmonary renal cell carcinoma metastases. Am J Surg. 2011 202(2):158–67. https://doi.org/10.1016/j.amjsurg.2010.06.029.

    Article  PubMed  Google Scholar 

  26. Murthy SC, Kim K, Rice TW, Rajeswaran J, Bukowski R, DeCamp MM, Blackstone EH. Can we predict long-term survival after pulmonary metastasectomy for renal cell carcinoma? Ann Thorac Surg. 2005 79(3):996–1003.

    Article  PubMed  Google Scholar 

  27. Pogrebniak HW, Haas G, Linehan WM, Rosenberg SA, Pass HI. Renal cell carcinoma: resection of solitary and multiple metastases. Ann Thorac Surg. 1992 54(1):33–8. Review.

    Article  CAS  PubMed  Google Scholar 

  28. Pfannschmidt J, Klode J, Muley T, Dienemann H, Hoffmann H. Nodal involvement at the time of pulmonary metastasectomy: experiences in 245 patients. Ann Thorac Surg. 2006 81(2):448–54.

    Article  PubMed  Google Scholar 

  29. Piltz S, Meimarakis G, Wichmann MW, Hatz R, Schildberg FW, Fuerst H. Long-term results after pulmonary resection of renal cell carcinoma metastases. Ann Thorac Surg. 2002 73(4):1082–7.

    Article  PubMed  Google Scholar 

  30. Ippen FM, Mahadevan A, Wong ET, Uhlmann EJ, Sengupta S, Kasper EM. Stereotactic radiosurgery for renal cancer brain metastasis: prognostic factors and the role of whole-brain radiation and surgical resection. J Oncol. 2015;2015:636918. https://doi.org/10.1155/2015/636918.

    Article  PubMed  PubMed Central  Google Scholar 

  31. Escudier B, Pluzanska A, Koralewski P, Ravaud A, Bracarda S, Szczylik C, Chevreau C, Filipek M, Melichar B, Bajetta E, Gorbunova V, Bay JO, Bodrogi I, Jagiello-Gruszfeld A, Moore N. AVOREN trial investigators. Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. Lancet. 2007 370(9605):2103–11.

    Article  PubMed  Google Scholar 

  32. Rini BI, Halabi S, Rosenberg JE, Stadler WM, Vaena DA, Archer L, Atkins JN, Picus J, Czaykowski P, Dutcher J, Small EJ. Phase III trial of bevacizumab plus interferon alfa versus interferon alfa monotherapy in patients with metastatic renal cell carcinoma: final results of CALGB 90206. J Clin Oncol. 2010 28(13):2137–43. https://doi.org/10.1200/JCO.2009.26.5561.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  33. Escudier B, Szczylik C, Hutson TE, Demkow T, Staehler M, Rolland F, Negrier S, Laferriere N, Scheuring UJ, Cella D, Shah S, Bukowski RM. Randomized phase II trial of first-line treatment with sorafenib versus interferon Alfa-2a in patients with metastatic renal cell carcinoma. J Clin Oncol. 2009 27(8):1280–9. https://doi.org/10.1200/JCO.2008.19.3342.

    Article  CAS  PubMed  Google Scholar 

  34. Escudier B, Eisen T, Stadler WM, Szczylik C, Oudard S, Staehler M, Negrier S, Chevreau C, Desai AA, Rolland F, Demkow T, Hutson TE, Gore M, Anderson S, Hofilena G, Shan M, Pena C, Lathia C, Bukowski RM. Sorafenib for treatment of renal cell carcinoma: Final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial. J Clin Oncol. 2009 27(20):3312–8. https://doi.org/10.1200/JCO.2008.19.5511.

    Article  CAS  PubMed  Google Scholar 

  35. Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, Rixe O, Oudard S, Negrier S, Szczylik C, Kim ST, Chen I, Bycott PW, Baum CM, Figlin RA. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med. 2007 356(2):115–24.

    Article  CAS  PubMed  Google Scholar 

  36. Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, Oudard S, Negrier S, Szczylik C, Pili R, Bjarnason GA, Garcia-del-Muro X, Sosman JA, Solska E, Wilding G, Thompson JA, Kim ST, Chen I, Huang X, Figlin RA. Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. J Clin Oncol. 2009 27(22):3584–90. https://doi.org/10.1200/JCO.2008.20.1293.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  37. Larkin J, Paine A, Foley G, Mitchell S, Chen C. First-line treatment in the management of advanced renal cell carcinoma: systematic review and network meta-analysis. Expert Opin Pharmacother. 2015;16(13):1915–27. https://doi.org/10.1517/14656566.2015.1058359.

    Article  CAS  PubMed  Google Scholar 

  38. Ravaud A, Motzer RJ, Pandha HS, George DJ, Pantuck AJ, Patel A, Chang YH, Escudier B, Donskov F, Magheli A, Carteni G, Laguerre B, Tomczak P, Breza J, Gerletti P, Lechuga M, Lin X, Martini JF, Ramaswamy K, Casey M, Staehler M, Patard JJ, et al. Adjuvant Sunitinib in high-risk renal-cell carcinoma after Nephrectomy. N Engl J Med. 2016 375(23):2246–54.

    Article  CAS  PubMed  Google Scholar 

  39. Haas NB, Manola J, Uzzo RG, Flaherty KT, Wood CG, Kane C, Jewett M, Dutcher JP, Atkins MB, Pins M, Wilding G, Cella D, Wagner L, Matin S, Kuzel TM, Sexton WJ, Wong YN, Choueiri TK, Pili R, Puzanov I, Kohli M, Stadler W, et al. Adjuvant sunitinib or sorafenib for high-risk, non-metastatic renal-cell carcinoma (ECOG-ACRIN E2805): a double-blind, placebo-controlled, randomised, phase 3 trial. Lancet. 2016 387(10032):2008–16. https://doi.org/10.1016/S0140-6736(16)00559-6.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  40. Sternberg CN, Davis ID, Mardiak J, Szczylik C, Lee E, Wagstaff J, Barrios CH, Salman P, Gladkov OA, Kavina A, Zarbá JJ, Chen M, McCann L, Pandite L, Roychowdhury DF, Hawkins RE. Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial. J Clin Oncol. 2010 28(6):1061–8. https://doi.org/10.1200/JCO.2009.23.9764.

    Article  CAS  PubMed  Google Scholar 

  41. Motzer RJ, Hutson TE, Cella D, Reeves J, Hawkins R, Guo J, Nathan P, Staehler M, de Souza P, Merchan JR, Boleti E, Fife K, Jin J, Jones R, Uemura H, De Giorgi U, Harmenberg U, Wang J, Sternberg CN, Deen K, McCann L, Hackshaw MD, et al. Pazopanib versus sunitinib in metastatic renal-cell carcinoma. N Engl J Med. 2013 369(8):722–31. https://doi.org/10.1056/NEJMoa1303989.

    Article  CAS  PubMed  Google Scholar 

  42. Escudier B, Porta C, Bono P, Powles T, Eisen T, Sternberg CN, Gschwend JE, De Giorgi U, Parikh O, Hawkins R, Sevin E, Négrier S, Khan S, Diaz J, Redhu S, Mehmud F, Cella D. Randomized, controlled, double-blind, cross-over trial assessing treatment preference for pazopanib versus sunitinib in patients with metastatic renal cell carcinoma: PISCES Study. J Clin Oncol. 2014 32(14):1412–8. https://doi.org/10.1200/JCO.2013.50.8267.

    Article  CAS  PubMed  Google Scholar 

  43. Motzer RJ, Haas NB, Donskov F, Gross-Goupil M, Varlamov S, Kopyltsov E, Lee JL, Melichar B, Rini BI, Choueiri TK, Zemanova M, Wood LA, Reaume MN, Stenzl A, Chowdhury S, Lim HY, McDermott R, Michael A, Bao W, Carrasco-Alfonso MJ, Aimone P, Voi M, et al. Randomized phase III trial of adjuvant Pazopanib versus Placebo after nephrectomy in patients with localized or locally advanced renal cell carcinoma. J Clin Oncol. 2017 35(35):3916–3923. https://doi.org/10.1200/JCO.2017.73.5324.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  44. Rini BI, Escudier B, Tomczak P, Kaprin A, Szczylik C, Hutson TE, Michaelson MD, Gorbunova VA, Gore ME, Rusakov IG, Negrier S, Ou YC, Castellano D, Lim HY, Uemura H, Tarazi J, Cella D, Chen C, Rosbrook B, Kim S, Motzer RJ. Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial. Lancet. 2011 378(9807):1931–9. https://doi.org/10.1016/S0140-6736(11)61613-9.

    Article  CAS  PubMed  Google Scholar 

  45. Motzer RJ, Nosov D, Eisen T, Bondarenko I, Lesovoy V, Lipatov O, Tomczak P, Lyulko O, Alyasova A, Harza M, Kogan M, Alekseev BY, Sternberg CN, Szczylik C, Cella D, Ivanescu C, Krivoshik A, Strahs A, Esteves B, Berkenblit A, Hutson TE. Tivozanib versus sorafenib as initial targeted therapy for patients with metastatic renal cell carcinoma: results from a phase III trial. J Clin Oncol. 2013 31(30):3791–9. https://doi.org/10.1200/JCO.2012.47.4940.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  46. Motzer RJ, Hutson TE, Glen H, Michaelson MD, Molina A, Eisen T, Jassem J, Zolnierek J, Maroto JP, Mellado B, Melichar B, Tomasek J, Kremer A, Kim HJ, Wood K, Dutcus C, Larkin J. Lenvatinib, everolimus, and the combination in patients with metastatic renal cell carcinoma: a randomised, phase 2, open-label, multicentre trial. Lancet Oncol. 2015 16(15):1473–82. https://doi.org/10.1016/S1470-2045(15)00290-9.

    Article  CAS  PubMed  Google Scholar 

  47. Choueiri TK, Escudier B, Powles T, Tannir NM, Mainwaring PN, Rini BI, Hammers HJ, Donskov F, Roth BJ, Peltola K, Lee JL, Heng DYC, Schmidinger M, Agarwal N, Sternberg CN, McDermott DF, Aftab DT, Hessel C, Scheffold C, Schwab G, Hutson TE, Pal S, et al. Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomised, open-label, phase 3 trial. Lancet Oncol. 2016 17(7):917–27. https://doi.org/10.1016/S1470-2045(16)30107-3.

    Article  CAS  PubMed  Google Scholar 

  48. Choueiri TK, Hessel C, Halabi S, Sanford B, Michaelson MD, Hahn O, Walsh M, Olencki T, Picus J, Small EJ, Dakhil S, Feldman DR, Mangeshkar M, Scheffold C, George D, Morris MJ. Cabozantinib versus sunitinib as initial therapy for metastatic renal cell carcinoma of intermediate or poor risk (Alliance A031203 CABOSUN randomised trial): progression-free survival by independent review and overall survival update. Eur J Cancer. 2018 94:115–25. https://doi.org/10.1016/j.ejca.2018.02.012.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  49. Thomas GV, Tran C, Mellinghoff IK, Welsbie DS, Chan E, Fueger B, Czernin J, Sawyers CL. Hypoxia-inducible factor determines sensitivity to inhibitors of mTOR in kidney cancer. Nat Med. 2006 12(1):122–7.

    Article  CAS  PubMed  Google Scholar 

  50. Hudes G, Carducci M, Tomczak P, Dutcher J, Figlin R, Kapoor A, Staroslawska E, Sosman J, McDermott D, Bodrogi I, Kovacevic Z, Lesovoy V, Schmidt-Wolf IG, Barbarash O, Gokmen E, O’Toole T, Lustgarten S, Moore L, Motzer RJ. Global ARCC Trial. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med. 2007 356(22):2271–81.

    Article  CAS  PubMed  Google Scholar 

  51. Motzer RJ, Escudier B, Oudard S, Hutson TE, Porta C, Bracarda S, Grünwald V, Thompson JA, Figlin RA, Hollaender N, Urbanowitz G, Berg WJ, Kay A, Lebwohl D, Ravaud A. RECORD-1 Study Group. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet. 2008 372(9637):449–56. https://doi.org/10.1016/S0140-6736(08)61039-9.

    Article  CAS  PubMed  Google Scholar 

  52. Finke J, Ferrone S, Frey A, Mufson A, Ochoa A. Where have all the T cells gone? Mechanisms of immune evasion by tumors. Immunol Today. 1999 20(4):158–60.

    Article  CAS  PubMed  Google Scholar 

  53. Medical Research Council Renal Cell Collaborators. Medical Research Council (MRC) Renal Cell Collaboration. Interferon-∝ and survival in metastatic renal carcinoma: early results of a randomized controlled trial. Lancet. 1999;353(9146):14–7.

  54. Fisher RI, Rosenberg SA, Fyfe G. Long-term survival update for high-dose recombinant interleukin-2 in patients with renal cell carcinoma. Cancer J Sci Am. 2000 6(Suppl 1):55-7.

    Google Scholar 

  55. Zitvogel L, Kroemer G. Targeting. PD-1/PD-L1 interactions for cancer immunotherapy. Oncoimmunology. 2012 1(8):1223–1225.

    Article  PubMed  PubMed Central  Google Scholar 

  56. Motzer RJ, Escudier B, McDermott DF, George S, Hammers HJ, Srinivas S, Tykodi SS, Sosman JA, Procopio G, Plimack ER, Castellano D, Choueiri TK, Gurney H, Donskov F, Bono P, Wagstaff J, Gauler TC, Ueda T, Tomita Y, Schutz FA, Kollmannsberger C, Larkin J, et al. Nivolumab versus everolimus in advanced renal-cell carcinoma. N Engl J Med. 2015 373(19):1803–13. https://doi.org/10.1056/NEJMoa1510665.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  57. Motzer RJ, Tannir NM, McDermott DF, Arén Frontera O, Melichar B, Choueiri TK, Plimack ER, Barthélémy P, Porta C, George S, Powles T, Donskov F, Neiman V, Kollmannsberger CK, Salman P, Gurney H, Hawkins R, Ravaud A, Grimm MO, Bracarda S, Barrios CH, Tomita Y, et al. Nivolumab plus Ipilimumab versus Sunitinib in advanced renal-cell carcinoma. N Engl J Med. 2018 378(14):1277–90. https://doi.org/10.1056/NEJMoa1712126.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  58. Gore ME, Szczylik C, Porta C, Bracarda S, Bjarnason GA, Oudard S, Hariharan S, Lee SH, Haanen J, Castellano D, Vrdoljak E, Schöffski P, Mainwaring P, Nieto A, Yuan J, Bukowski R. Safety and efficacy of sunitinib for metastatic renal-cell carcinoma: an expanded-access trial. Lancet Oncol. 2009 10(8):757–63. https://doi.org/10.1016/S1470-2045(09)70162-7.

    Article  CAS  PubMed  Google Scholar 

  59. Stadler WM, Figlin RA, McDermott DF, Dutcher JP, Knox JJ, Miller WH Jr, Hainsworth JD, Henderson CA, George JR, Hajdenberg J, Kindwall-Keller TL, Ernstoff MS, Drabkin HA, Curti BD, Chu L, Ryan CW, Hotte SJ, Xia C, Cupit L, Bukowski RM, ARCCS Study Investigators. Safety and efficacy results of the advanced renal cell carcinoma sorafenib expanded access program in North America. Cancer. 2010 116(5):1272–80. https://doi.org/10.1002/cncr.24864.

    Article  CAS  PubMed  Google Scholar 

  60. Dudek AZ, Raza A, Chi M, Singhal M, Oberoi R, Mittapalli RK, Agarwal S, Elmquist WF. Brain metastases from renal cell carcinoma in the era of tyrosine kinase inhibitors. Clin Genitourin Cancer. 2013 11(2):155–60. https://doi.org/10.1016/j.clgc.2012.11.001.

    Article  PubMed  Google Scholar 

  61. Massard C, Zonierek J, Gross-Goupil M, Fizazi K, Szczylik C, Escudier B. Incidence of brain metastases in renal cell carcinoma treated with sorafenib. Ann Oncol. 2010 21(5):1027–31. https://doi.org/10.1093/annonc/mdp411.

    Article  CAS  PubMed  Google Scholar 

  62. Calvo E, Schmidinger M, Heng DY, Grünwald V, Escudier B. Improvement in survival end points of patients with metastatic renal cell carcinoma through sequential targeted therapy. Cancer Treat Rev. 2016 50:109–117. https://doi.org/10.1016/j.ctrv.2016.09.002.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Uro-oncology, Maria Sklodowska-Curie Memorial Cancer Centre and Institute of Oncology, 5, Roentgen Street, 02-781, Warsaw, Poland

    Pawel Wiechno, Jakub Kucharz, Malgorzata Sadowska, Wojciech Michalski, Bozena Sikora-Kupis, Joanna Jonska-Gmyrek, Grazyna Poniatowska, Karol Nietupski & Tomasz Demkow

  2. Department of Urology, The John Paul II District Hospital in Kolbuszowa, Kolbuszowa, Poland

    Krzysztof Ossolinski

Authors
  1. Pawel Wiechno
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Jakub Kucharz
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Malgorzata Sadowska
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Wojciech Michalski
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Bozena Sikora-Kupis
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Joanna Jonska-Gmyrek
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Grazyna Poniatowska
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Karol Nietupski
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Krzysztof Ossolinski
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Tomasz Demkow
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Jakub Kucharz.

Ethics declarations

Conflict of interest

Pawel Wiechno has received speakers’ honoraria and travel grants from Pfizer, Bayer, Novartis, and IPSEN. Jakub Kucharz has received research grant from Novartis, travel grants and speakers’ honoraria from Pfizer, Bayer, Novartis, and IPSEN. Other authors declare no conflicts of interest.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Wiechno, P., Kucharz, J., Sadowska, M. et al. Contemporary treatment of metastatic renal cell carcinoma. Med Oncol 35, 156 (2018). https://doi.org/10.1007/s12032-018-1217-1

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1007/s12032-018-1217-1

Keywords

Search

Navigation